- Management to discuss second quarter financial results -
LAVAL, QC, July 25 /CNW/ - Labopharm Inc. (TSX: DDS; NASDAQ: DDSS) today
announced that it will host a conference call on Friday, August 8 at 8:30 a.m.
(ET) to discuss its second quarter 2008 financial results. Labopharm will
report its second quarter 2008 financial results via news release at
approximately 7:00 a.m. the same day.
To access the conference call by telephone, dial 416-646-3095 or
1-800-814-4859. Please connect approximately 15 minutes prior to the beginning
of the call to ensure participation. The conference call will be archived for
replay until Friday, August 15, 2008 at midnight. To access the archived
conference call, dial 416-640-1917 or 1-877-289-8525 and enter the reservation
number 21278611 followed by the number sign.
A live audio webcast of the conference call will be available at
www.labopharm.com. Please connect at least 15 minutes prior to the conference
call to ensure adequate time for any software download that may be required to
join the webcast. The webcast will be archived at the above web site for
About Labopharm Inc.
Labopharm is an emerging leader in optimizing the performance of existing
small molecule drugs using its proprietary controlled-release technologies.
The Company's lead product, a unique once-daily formulation of tramadol, is
being commercially launched in key markets globally. The Company also has a
robust pipeline of follow-on products in both pre-clinical and clinical
development. Labopharm's vision is to become an integrated, international,
specialty pharmaceutical company with the capability to internally develop and
commercialize its own products. For more information, please visit
This press release contains forward-looking statements, which reflect the
Company's current expectations regarding future events. The forward-looking
statements involve risks and uncertainties. Actual events could differ
materially from those projected herein and depend on a number of factors,
including the uncertainties related to the regulatory process in various
countries for the approval of the Company's products and the successful
commercialization of the products throughout the world if they are approved.
Investors should consult the Company's ongoing quarterly filings and annual
reports for additional information on risks and uncertainties relating to
these forward-looking statements. The reader is cautioned not to rely on these
forward-looking statements. The Company disclaims any obligation to update
these forward-looking statements.
For further information:
For further information: At Labopharm, Mark D'Souza, Senior
Vice-President and Chief Financial Officer, Tel: (450) 686-0207; At The
Equicom Group, Jason Hogan, Media and Investor Relations, Tel: (416) 815-0700,
email@example.com; French: Joe Racanelli, Tel: (514) 844-7997,